Synergistic effect of remdesivir and pegylated interferon alfa 1 beta in treatment of Covid 19

Background: Pharmacological therapies of proven efficacy in corona virus disease 2019 are still lacking with no antiviral treatment. Impaired type I interferon activity may be responsible for severe COVID-19 patient. We performed prospective, observational, open-label study to evaluate the and safety a single dose Pegylated IFN-α2b addition Remdesivir moderate cases. Aim: The aim this is assess role synergistic effect Interferon alfa 2 Beta COIVID-19 disease. Materials Methods: 24 subjects covid included. Subjects were given PEG (1 μg/kg subcutaneous [SC] injection, dose) plus other standard treatment protocol (MoHFW).We observed oxygen saturation respiratory rate at discharge duration hospital stay impact comorbidities on same. Results: In admission mean SpO2 was 90.25 ± 2.454% 95.13 1.872%.At RR 23.00 2.670 bpm 18.71 1.546 bpm. Mean illness 7.88 2.112 days. HRCT score 12.21 2.889.Mean days recovery 7.29 3.329 There significant change o2 respect co morbidities. Conclusions: This provides evidence potential use 1 improvement clinical status likely due faster viral reduction. Further confirmatory studies required support data study.